News

In December 2023, it was announced that Canada’s Drug Agency would be built from CADTH. The work of the drug agency expands on CADTH’s existing mandate and functions — which spans drugs, medical devices, and clinical interventions — and includes new work streams such as: improving the appropriate…
A Statement From Suzanne McGurn, President and CEO, CADTH On behalf of the organization and our Board of Directors, I’m pleased to share the Annual Report for 2023–2024. The theme this year, Partnering for Results, aligns with our Strategic Plan and demonstrates how meaningful partnerships are…
Target Zero is a new initiative that aims to improve the time to access for patients in Canada for new drugs that are proven to be effective. The ambitious goal of Target Zero is to achieve zero days between Health Canada’s regulatory approval of a drug and CADTH’s reimbursement recommendation to…
CADTH has developed a comprehensive and accessible tool to support the validation of economic models used in health technology assessments (HTAs). Economic models are integral components of a HTA that help demonstrate the value of health technologies (e.g., drugs or medical devices). Validating…
We are testing a new approach that brings the societal perspective to our economic evaluations of certain new drugs. When a drug sponsor submits a drug to our Drug Reimbursement Review program for review, they provide an economic model as part of their evidence package. As described in our…
Current Consultation Status: ClosedConsultation Period Extended: March 28 to May 3, 2024 CADTH is updating the procedures for provisional funding algorithms as part of our commitment to examine new ways of working and our ongoing efforts to improve the drug reimbursement pathway. The provisional…
Qualified rare disease registry owners can submit funding proposals to enhance the infrastructure, data quality, and utility of rare disease registries. CADTH is launching an open call for funding to support efforts to improve the quality and usability of real-world data from rare disease…
Submission deadline: Friday, May 10, 2024 Nominations are now being accepted for 4 prestigious awards for outstanding achievement in the field of health technology assessment (HTA) in Canada. The Dr. Jill M. Sanders Award of Excellence in Health Technology Assessment recognizes individuals whose…
CADTH and Choosing Wisely Canada have convened a time-limited advisory panel to provide guidance on the minimum retesting intervals for 5 commonly used lab tests in Canada. Lab testing is a critical component of effective patient care and is a high-volume medical activity in Canada. The importance…
The field of complex care for children and youth is evolving, bringing forth new technologies and ways of providing care. A new CADTH report sheds light on the top technologies and issues that could shape the future of health care for children and youth with medical complexity.   Children and…
CADTH is seeking nominations for its expert and advisory committees. We are currently accepting applications from individuals with significant expertise working in various health care systems in Canada, who are interested in helping support health care decision-makers in making informed decisions…
On Rare Disease Day — a day when the international community raises awareness about rare conditions and their impact on patients’ lives — CADTH is announcing new work related to drugs for rare diseases.  In March 2023, the Government of Canada announced the National Strategy for Drugs for Rare…